Skip to main content
TTrialFinder
TrialFinder is for informational purposes only and does not provide medical advice. Always talk to your doctor.
RECRUITINGOBSERVATIONAL

PRagmatic Study Of Messaging to Providers of Patients With Heart Failure in Amsterdam UMC

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.

About This Trial

This is a prospective cohort study, where the investigators aim to investigate the effect of implementation of an electronic nudge alerting clinicians to the prescription of the 4 key pharmacological classes for the treatment of patients with heart failure and reduced ejection fraction (HFrEF) at the outpatient clinic in the Netherlands.

Who May Be Eligible (Plain English)

Who May Qualify: - Age \> 18 years - Treatment for HFrEF at the outpatient clinic cardiology. - Documented reduced ejection fraction of \<40% based on cardiac ultrasound or cardiac magnetic resonance imaging. Who Should NOT Join This Trial: - Opt-out for the use of routine clinical data for research purposes Always talk to your doctor about whether this trial is right for you.

Original Eligibility Criteria

View original clinical language
Inclusion Criteria: * Age \> 18 years * Treatment for HFrEF at the outpatient clinic cardiology. * Documented reduced ejection fraction of \<40% based on cardiac ultrasound or cardiac magnetic resonance imaging. Exclusion Criteria: * Opt-out for the use of routine clinical data for research purposes

Treatments Being Tested

OTHER

Best practice alert for the notification of patients with HFrEF and recommended evidence-based therapies

An algorithm will check if the patients if the patient has an age \>18 year and is treated at the cardiology department for HFrEF. The use of GDMT is determined using prescriptions data electronic health records (EHR). If the patient does not receive treatment for all 4 drug classes (ACE/ARB/ARNi, beta-blocker, MRA, SGLT2-inhibitor), an electronic alert will be displayed suggesting the clinician to prescribe additional medication when clinically indicated, including relevant recent laboratory results (renal function and electrolytes) and other relevant measures (LVEF, blood pressure and heart rate). The alert is linked to an order set to aid in the prescription of GDMT according to current guidelines. Results will compared to a retrospective cohort (t=-12 to t=-6) months, and a silent mode cohort (t=-6 to t=0 months, in which a paired and a before and after analysis will be performed to evaluate the effect of the alert.

Locations (2)

Amsterdam University Medical Centers, Location AMC
Amsterdam, Netherlands
Amsterdam University Medical Centers, Location VU Medical Center
Amsterdam, Netherlands